9. Nelson WH and Khan A.
Age effects on the dexamethasone suppression test in unipolar major depression.
Neuroendocrinology letters 9:181, 1987.

10. Khan A and Dunner DL.
Clinical predictors of placebo response in depressed outpatients.
Panel presentation at 26th Annual Meeting of American College of Neuropsychopharmacology (Abstract, p. 58), 1987.

11. Avery D, Khan A and Cohen S.
Bright light treatment of SAD: AM vs PM light.
Symposium at World Psychiatric Association Washington, DC (Abstract), 1988.

12. Khan A.
Acute treatment of psychotic depression.
Clinical Advances in the Treatment of Psychiatric Disorders 2; 4: 4, 1988.

13. Khan A and Dunner DL.
Study group participant on placebo response at the 27th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 56), 1988.

14. Cohen S and Khan A.
Hospitalization effect on acute exacerbation of schizophrenia.
Schizophrenia Research 2: 220, 1989.

15. Khan A, Dager S and Dunner DL.
Clinical and demographic features related to placebo and antidepressant response.
Biological Psychiatry 25:79-80A, 1989, (Suppl).

16. Khan A.
Book Review on "Electroconvulsive Therapy" by Richard Abrams, MD, 1988.
Journal of Nervous and Mental Disease 177:501-502, 1989.

17. Khan A.
Study group participant on placebo response in depression at the 28th Annual Meeting of the American College of Neuropsychopharmacology, (Brown and Dunner, Abstract, p. 44), 1989.

18. Khan A, Dager S, Cohen S, Avery D and Dunner DL.
When is the onset of response to antidepressant?
28th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 198), 1989.

19. Dager S, Khan A, Cowley DC, Avery DH, Elder J, Roy-Byrne P and Dunner DL. Clinical characteristics of placebo response among panic patients.
28th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 183), 1989.

20. Cohen S, Khan A and Cox G.
Demographic and clinical features predictive of recovery in acute mania. Psychiatry Digest 6:23-25, 1990.

21. Khan A and Brown WA.
Who should receive antidepressants: suggestions from placebo treatment.
29th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 138) December, 1990.

22. Khan A, Mirolo MH, Horita A, Lampe T and Tucker GJ.
TRH in ECT/ECS post-ictal state.
30th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 233), 1991.

23. Khan A, Lai H, Mirolo MH and Ukai Y.
TRH and ECT: Cholinergic involvement in cognitive deficit state.
31st Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 106) 1992.

24. Khan A.
Book review on "Electroconvulsive Therapy" by Richard Abrams, Second Edition.
Journal of Nervous and Mental Disease 181: 592, 1993.

25. Khan A, Steiert J and Githens S.
Effective Collaboration with Managed Care.
146th Annual Meeting of the American Psychiatric Association, (Issue Workshop #12, Abstract p. 303-304), 1993.

26. Khan A, Mirolo MH, Claypoole K, Lai H, and Tucker G.
Low-dose TRH effects in ECT post-ictal state.
Annual Meeting of the Society of Biological Psychiatry (Abstract, p 654), 1994.

27. Khan A, Lai H, Nishimura Y, Mirolo MH, and Singh NP.
ECS effects on neuronal DNA strand breaks.
Annual Meeting of the Society of Biological Psychiatry. (Abstract, p. 664).

28. Singh NP, Malik S, Kenny MA, Lai H, and Khan A.
Acetaldehyde induced DNA single strand breaks in human lymphocytes.
Annual Meeting of the Society of Biological Psychiatry. (Abstract, p. 708).

29. Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivatsava R, and Mirolo MH.
Venlafaxine in depressed geriatric outpatients: an open label study.
XIXth CINP Congress, 1994. (Abstract, p. 163S).

30. Ferguson J, Khan A, Kucharik R, Leventer S, and Cucci C.
A placebo-controlled comparative study of the effects on blood pressure and antidepressant efficacy of venlafaxine and imipramine.
XIXth CINP Congress, 1994. (Abstract, p. 165S).

31. Khan A, and Montgomery N.
Seizure Inhibition Syndrome.
Annual Meeting of the Association for convulsive Therapy, 1995 (Abstract in Convulsive Therapy, p. 70).

32. Khan A.
Overall safety profile of venlafaxine: a commentary.
An invited abstract for Psychiatry Digest, February, 1997 (Abstract p. 27-28).

33. Khan A.
Panel Participant: IMGs and ABPN Performance, APA Annual meeting (p.36) 1997.

34. Khan, A, Warner H and Brown WA.
Placebo in Antidepressant Clinical trials: Efficacy and safety.
36th Annual Meeting of the American College of Neuropsychopharmacology, December, 1997 (Abstract p.138).

35. Khan A, (Chair) Walter A. Brown (Moderator) and Quitkin F (ACNP Invitee). Are placebo controls ethical in antidepressant clinical trials?
Study Group at the 37th Annual Meeting of the American College of Neuropsychopharmacology, 1998

36. Cookson J, Khan A, Asnis P et al.
Profile of antidepressant activity of lamotrigine (Lamictal) in Bipolar and Unipolar Depression: Results from double-blind, placebo-controlled studies.
12th Annual meeting of the European College of Neuropsychopharmacology b(Abstract), September 1999.

37. Asnis G, Beaman M, Bowden C, Calabrese, De Veaugh-Geiss, Evoniuk G, Huffman R and Khan A.
Efficacy of lamotrigine in bipolar and unipolar depression: results from double-blind, placebo-controlled studies.
38th Annual Meeting of the American College of Neuropsychopharmacology, December 1999 (Abstract p. 162).

38. Khan A and Khan S.
Are placebo controls ethical in antidepressant clinical trials?
Invited Article for Psychiatric Times, XVII: 4 29, April 2000.

39. Khan A, Warner H, Brown WA.
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials.
Archives of General Psychiatry, April, 2000, vol. 57, American Medical Association. pp 311-317 (see also pages 319, 321, 323, 325, 327 & 329)

40. Huffman R, Ascher J, Khan A, and Calabrese J.
Evaluation of Efficacy and Safety of Lamotrigine for the Long-Trem Treatment of Bipolar Depression.
NCDEU, poster #51, 2000.

41. Earl N, Greene P, Ascher J, Fouche N, Chang C, Evoniuk G, Swann A, Pope S, Ketter T, McElroy S, Post R, Zajecka J, Altshuler L, Apter J, Wets S, Risch C and Khan A.
Mood stabilization with lamotrigine in rapid cycling bipolar disorder.
ECNP Annual Meeting, Munich, September, 2000.

42. Labetelle M, Zumbrunnen T, Brennan J, Biederman J, Connor J, Emslie G, Ferguson J, Khan A, Ruckle J, Sallee R and Riddle M.
Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.
Poster presentation child neuropsychiatry conference (Pisa) May, 2000.

43. Khan A, Khan S, Leventhal R, Brown WA.
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the FDA database.
39th Annual meeting of the American College of neuropsychopharmacology (#178), 2000.

44. Suppes T, Altshuler L, Apter J, Bowden C, Calabrese J, Ginsberg L, Goldberg J, Gyulai L, Khan A, McElroy S, Rapaport M, Risch S, Scahs G, Swann A, West S, Zajecka J, Ascher J, Barrows C, Earl N, Greene P.
Mood stabilization with lamotrigine in rapid cycling bipolar disorder: a double-blind placebo-controlled study.
39th Annual meeting of the American College of Neuropsychopharmacology (#99), 2000.

45. Khan A, Khan SR, Brown WA.
Do psychotropics reduce suicide risk?
40th Annual Meeting of the American College of Neuropsychophamacology (#159, p. 186), 2001

46. Pollock MH, Feltner, DE, Rickels K, Lydiard RB, Zimbroff DL, Bieski RJ, Khan A, Goodrich J, Brock JD, Pande AC.
A placebo-controlled, double-blind study of pregabalin treatment of generalized anxiety disorder.
40th Annual Meeting of the American College of Neuropsychopharmacology (#46, p. 337), 2001.

47. Bowden C, Ghaemi N, Gyulai L, Huey L, Khan A, Montgomery P and Ascher, J.
lamotrigine delays mood episodes in recently depressed bipolar I patients.
Annual meeting of American Psychiatric Association, 2002 (in press)

48. Khan A, Khan S, Walens G, Giller E.
Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration Summary Basis of Approval reports.
41st Annual Meeting of the American College of Neuropsychopharmacology (poster) 2002

49. Khan A, Khan S, Kolts R, Brown WA.
Suicide rate with SSRI antidepressants compared to other antidepressants and placebo.
41st Annual Meeting of the American College of Neuropsychopharmacology (poster) 2002

50. Khan A, Khan S, Kolts R, Brown WA.
Research design factors associated with anstidepressant clinical trial outcome.
New Clinical Drug Evaluation Unit (NCDEU), May 2003.

51. Khan A, Kolts R, Brown WA.
Research Design Features associated with antidepressant clinical trial outcome.
42nd Annual meeting of the American College of Neuropsychopharmacology (poster) 2003.

52. Khan A, Brodhead AE, Kolts RL, Brown WA.
Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Clinical Global Impressions Rating Scale in antidepressant clinical trials.
New Clinical Drug Evaluation Unit (NCDEU) (poster #174), June 2004.

53. Khan A, Brodhead AE, Kolts RL, Brown WA.
Severity of depressive symptoms and response to antidepressants and placebo in antidepressant clinical trials.
New Clinical Drug Evaluation Unit (NCDEU) (poster #176), June 2004.

54. Khan A, Brodhead AE, Lai H, Singh NP.
Commercial potential of toxins, developing toxins for applications in drug discovery and diagnostics.
International Society on Toxinology- European Section, 15th European Symposium on Animal, Plant and Microbial Toxins, June 2004.

55.
Khan A, Schwartz TL.
Tiagabine as an efficacious augmentation therapy to selective serotonin reuptake inhibitors in patients with generalized anxiety disorder.
17th European College of Neuropsychopharmacology (ECNP), October 2004.

56. Khan A, Brodhead AE, Kolts RL, Brown WA.
Sex differences in SSRI antidepressant response among outpatients participating in antidepressant clinical trials.
43rd Annual meeting of American College of Neuropsychopharmacology, December 2004.

57. Khan A, Schwartz KA, Kolts RL, Brodhead AE, Brown WA.
Sex differences and BMI in relation to antidepressant clinical trial outcomes.
New Clinical Drug Evaluation Unit (NCDEU), June 2005.

58. Khan A, Schwartz KA.
Clinical Trials: 20-year Trends and Predictors of Success.
New Clinical Drug Evaluation Unit (NCDEU), June 2005.

59. Khan A, Alper K, Schwartz K, Kolts R, Brown W.
Seizure Risk Among Patients Participating in Psychopharmacology Clinical Trials.
Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2005.

60. Khan A, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W.
Frequency of suicides, suicide attempts, seizures, and mortality in psychopharmacological clinical trials.
APA Lunch Forum: Hot Topics in Psychopharmacology and Drug Safety. Annual Meeting of American Psychiatric Association (APA), May 2006.

61. Khan A, Farfel GM, Brock JD, Kavousi R, Chatamra K.
Efficacy and safety of pregabalin for the treatment of generalized anxiety disorder in elderly patients (poster).
Annual Meeting of American Psychiatric Association (APA), May 2006.

62. Khan A, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W.
Seizure, suicide, and mortality among psychiatric patients based on FDA SBA reports (poster).
Annual Meeting for New Clinical Drug Evaluation Unit (NCDEU), June 2006.

63. Khan A, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W.
Frequency of suicides, suicide attempts, seizures, and mortality in psychopharmacological clinical trials.
Enhancing Precision in Clinical Trials: Recruitment, Study Design, Measurement, Endpoints. Annual Meeting for New Clinical Drug Evaluation Unit (NCDEU), June 2006.

64. Khan A, Schwartz K, Kolts RL, Ridgway D, Redding N, Lineberry C. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2006.

65. Brown WA, Redding N, Kolts RL, Khan A.
The persistence of the placebo response in antidepressant clinical trials.
Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2006.